Related Experiment Video
Updated: Apr 28, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary
Koji Goto1, Kentaro Nakai1, Satoshi Shizuta1
1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Insights
Oral anticoagulation (OAC) was underused and suboptimal in atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI). This led to inadequate stroke prevention, highlighting a need for improved OAC management in real-world settings.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) require careful management of antithrombotic therapy.
- The combined use of oral anticoagulation (OAC) and dual antiplatelet therapy (DAPT) presents challenges in balancing efficacy and safety.
- Real-world data on OAC use in AF patients post-PCI is limited.
Purpose of the Study:
- To evaluate the real-world prevalence, intensity, safety, and efficacy of OAC in patients with AF undergoing PCI.
- To assess the impact of OAC use and its intensity (Time in Therapeutic Range - TTR) on stroke incidence.
- To examine the outcomes of continuing DAPT alongside OAC in this patient population.
Main Methods:
- Retrospective analysis of the Coronary REvascularization Demonstrating Outcome Study in Kyoto registry cohort-2.
- Inclusion of 1,057 patients with AF undergoing first PCI.
- Comparison of stroke incidence between OAC and no-OAC groups, and analysis of TTR and its association with outcomes.
Main Results:
- AF patients had a higher 5-year stroke incidence (12.8%) compared to non-AF patients (5.8%).
- OAC was underused (47.9% of eligible patients) and intensity was suboptimal, with a mean TTR of 52.6%.
- Adequate TTR (≥65%) was associated with significantly lower stroke incidence (6.9% vs 15.1%).
Conclusions:
- OAC is underutilized and inadequately managed in real-world AF patients post-PCI, leading to insufficient stroke prevention.
- Suboptimal OAC intensity (low TTR) is linked to increased stroke risk.
- Continuing long-term DAPT with OAC did not demonstrate a reduction in stroke incidence in this cohort.
Abstract:
The prevalence, intensity, safety, and efficacy of oral anticoagulation (OAC) in addition to dual antiplatelet therapy (DAPT) in "real-world" patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not yet been fully evaluated. In the Coronary REvascularization Demonstrating Outcome Study in Kyoto registry cohort-2, a total of 1,057 patients with AF (8.3%) were identified among 12,716 patients undergoing first PCI. Cumulative 5-year incidence of stroke was higher in patients with AF than in no-AF patients (12.8% vs 5.8%, p <0.0001). Although most patients with AF had CHADS2 score ≥2 (75.2%), only 506 patients (47.9%) received OAC with warfarin at hospital discharge. Cumulative 5-year incidence of stroke in the OAC group was not different from that in the no-OAC group (13.8% vs 11.8%, p = 0.49). Time in therapeutic range (TTR) was only 52.6% with an international normalized ratio of 1.6 to 2.6, and only 154 of 409 patients (37.7%) with international normalized ratio data had TTR ≥65%. Cumulative 5-year incidence of stroke in patients with TTR ≥65% was markedly lower than that in patients with TTR <65% (6.9% vs 15.1%, p = 0.01). In a 4-month landmark analysis in the OAC group, there was a trend for higher cumulative incidences of stroke and major bleeding in the on-DAPT (n = 286) than in the off-DAPT (n = 173) groups (15.1% vs 6.7%, p = 0.052 and 14.7% vs 8.7%, p = 0.10, respectively). In conclusion, OAC was underused and its intensity was mostly suboptimal in real-world patients with AF undergoing PCI, which lead to inadequate stroke prevention. Long-term DAPT in patients receiving OAC did not reduce stroke incidence.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome IV: Interprofessional Care

